Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Sudden painless vision loss: triage

Acute vision loss is a time-critical presentation that must be triaged quickly to separate benign causes from ophthalmic and neurological emergencies, often by non-ophthalmic clinicians [S11]. Acute retinal artery occlusion presents with sudden, painless monocular vision loss and is equivalent to a cerebral stroke [S12]. Giant cell arteritis (GCA) can cause irreversible loss in one or both eyes [S6].

Key points - Treat sudden painless monocular vision loss as a possible stroke: retinal artery occlusion needs a standard stroke evaluation [S12]. - Acute cerebral ischaemia was found on MRI in 30% of patients with central retinal artery occlusion (CRAO) and 25% with branch occlusion (BRAO) [S8]. - Transient monocular vision loss (amaurosis fugax) is a transient ischaemic attack and needs the same urgent work-up as stroke [S9]. - Stroke risk is highest in the first few days; eye care professionals should refer immediately to a stroke centre rather than performing further tests themselves [S7]. - Consider GCA; vision loss is its most feared and irreversible complication [S6].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Sudden painless monocular loss (possible CRAO or BRAO) [S12].
• Transient monocular loss, which portends possible future vision loss and stroke [S4] [S9].
• Features of GCA [S6] [S11].
• Other conditions needing immediate specialist involvement: acute angle-closure glaucoma, retinal detachment and optic neuritis [S11].
• Cardiovascular risk factors in a patient with retinal artery occlusion: atrial fibrillation, heart failure, valvular heart disease, dyslipidaemia and smoking were linked to stroke [S10].

Recognise it

• A five-step approach: (1) one eye or both, (2) painful or painless, (3) targeted history, (4) focused chairside examination for red flags, (5) action by escalation, investigation and referral [S11].
• Duration: transient loss lasts less than 24 hours and persistent loss more than 24 hours [S2].
• CRAO: over three-quarters of patients have profound loss, with acuity of 20/400 or worse [S1]. CRAO includes non-arteritic, transient non-arteritic, cilioretinal-sparing and arteritic forms [S1].
• Non-arteritic anterior ischaemic optic neuropathy (NAION) is the most common cause of acute optic nerve injury in adults and older people [S5].
• Transient loss may reflect carotid occlusion or thromboembolism, or a benign cause such as migraine or vasospasm [S4].

Confirm it

• Fundus examination confirms retinal artery occlusion, helped by fundus photography and OCT [S12].
• Do not delay transfer for further eye tests in acute retinal arterial ischaemia [S7].
• Stroke work-up: urgent brain MRI with diffusion-weighted imaging, vascular imaging and clinical assessment are recommended for transient loss, BRAO and CRAO [S7]. Imaging of the brain and the extracranial and intracranial vessels is the cornerstone of TIA work-up, with cardiac and blood tests [S9].
• Most acute cerebral ischaemia in these patients is asymptomatic: 22% of CRAO and 29% of BRAO cohorts had silent lesions [S8].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

1. Act at once. Educate patients to call emergency services for acute vision loss, so they are taken straight to a facility linked to a stroke centre [S12].
2. Refer immediately any suspected retinal arterial ischaemia or transient monocular loss to a stroke service [S7].
3. Possible GCA: refer urgently through a fast-track pathway where available [S6]; see the GCA article for treatment.

Tier B (general eye clinic)

• Confirm the diagnosis on fundus examination and transfer without further testing [S7] [S12].
• "Conservative treatments" such as anterior chamber paracentesis, ocular massage and haemodilution have no benefit and should not be pursued [S12].
• NAION: no widely accepted evidence-based treatment exists; measures to protect the other eye have only theoretical bases [S5]. Look for systemic associations [S5].

Tier C (specialist centre)

• Thrombolysis: meta-analyses and expert reviews suggest a possible treatment effect of IV tPA within 4.5 hours or intra-arterial tPA within 6 hours of vision loss in CRAO; trials are ongoing and there are no widely accepted therapies yet [S12]. No therapy is guideline-endorsed [S1].
• Secondary prevention of cerebral ischaemia is the mainstay of management [S4] [S9]: antiplatelet therapy, healthy lifestyle and control of hypertension, dyslipidaemia and diabetes, plus specific treatment of symptomatic carotid stenosis greater than 50%, aortic arch atheroma or atrial fibrillation [S9].
• Carotid stenosis: after carotid-related symptoms, pooled stroke risk with active follow-up was 6.0% at 2 to 3 days, 10.9% at 7 days and 17.6% at 14 days, supporting surgery as soon as possible [S3].
• Hospital admission is recommended for patients presenting within 72 hours of transient symptoms who meet high-risk criteria [S4].

Refer when

Pitfalls

• Doing ocular massage or paracentesis instead of transferring the patient [S12].
• Dismissing transient loss because vision has recovered [S4] [S9].
• Delaying transfer for additional eye investigations [S7].
• Forgetting cardiac risk factors and silent brain infarcts in retinal artery occlusion [S8] [S10].
• Missing GCA as the cause [S6].

Evidence notes

• Two meta-analyses support the stroke association [S8] [S10]; management advice is from expert and guideline reviews [S7] [S9] [S12].
• Thrombolysis for CRAO remains unproven; RCTs of tPA have been investigated and new trials are ongoing [S1] [S12].
• The stroke-centre pathway assumes access to MRI and stroke services; the sources do not address settings without them.
• Not covered by these sources: retinal vein occlusion, vitreous haemorrhage, GCA treatment doses, and functional or non-organic vision loss.

Related articles

• Central Retinal Artery Occlusion: An Ocular Stroke
• Rhegmatogenous Retinal Detachment
• Giant Cell Arteritis
• Retinal Vein Occlusion

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.